デフォルト表紙
市場調査レポート
商品コード
1439068

骨粗しょう症治療薬・骨折治癒市場 - 世界の産業規模、シェア、動向、機会、予測:薬剤タイプ別、投与経路別、流通チャネル別、地域別、競合、2018年~2028年

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition

出版日: | 発行: TechSci Research | ページ情報: 英文 190 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

骨粗しょう症治療薬・骨折治癒市場 - 世界の産業規模、シェア、動向、機会、予測:薬剤タイプ別、投与経路別、流通チャネル別、地域別、競合、2018年~2028年
出版日: 2024年01月07日
発行: TechSci Research
ページ情報: 英文 190 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の骨粗しょう症治療薬・骨折治癒市場は、2022年に140億2,000万米ドルと評価され、2028年までのCAGRは3.14%で、予測期間中に着実な成長が予測されています。

骨粗しょう症は、骨の弱体化を特徴とする広範な骨格障害であり、骨折のリスクを高め、その後、骨折治癒の合併症を引き起こします。この疾患は、特に世界人口の高齢化が進む中、世界の健康上の大きな課題となっています。世界の骨粗しょう症治療薬・骨折治癒市場は、医療専門家、製薬会社、医学研究者がこの衰弱状態に立ち向かおうとしているため、目覚ましい成長と技術革新を目の当たりにしています。骨粗しょう症は、骨折が起こるまで自覚症状がないまま進行するため、しばしば「沈黙の病」と呼ばれます。骨粗しょう症になると、骨は密度と強度を失い、多孔質でもろくなります。その結果、特に股関節、脊椎、手首で骨折しやすくなります。骨粗しょう症は主に閉経後の女性が罹患しますが、男性やあらゆる年齢の人にも影響を及ぼす可能性があります。

市場概要
予測期間 2024-2028
市場規模:2022年 140億2,000万米ドル
市場規模:2028年 167億6,000万米ドル
CAGR 2023-2028 3.14%
急成長セグメント カルシトニン
最大市場 北米

同市場では、薬物療法、医療機器、外科的処置、生活習慣の改善など、多様な治療オプションが提供されています。これらの選択肢は、骨粗しょう症の治療だけでなく、骨折後の治癒プロセスを高めることも目的としています。低侵襲手術技術や再生療法などの最先端技術は、骨粗しょう症治療薬・骨折治癒の効果を高めています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別(カルシトニン、ビスフォスフォネート、ホルモン補充療法、アナボリック、その他)
    • 投与経路別(経口、注射)
    • 流通チャネル別(病院薬局、小売薬局、eコマース)
    • 地域別
    • 企業別(2022年)
  • 市場マップ
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 地域別

第5章 アジア太平洋地域の骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州の骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米の骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米の骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカの骨粗しょう症治療薬・骨折治癒市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 薬剤タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

第12章 世界の骨粗しょう症治療薬・骨折治癒市場:SWOT分析

第13章 ポーターのファイブフォース分析

第14章 競合情勢

  • GlaxoSmithKline plc
  • Medtronic Plc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd
  • Stryker Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Orthofix US LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 21692

Global Anti Osteoporosis Therapy and Fracture Healing Market was valued at USD 14.02 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 3.14% through 2028. Osteoporosis is a pervasive skeletal disorder characterized by weakened bones, increasing the risk of fractures and, subsequently, fracture healing complications. This condition poses a significant global health challenge, especially as the world's population continues to age. The global anti-osteoporosis therapy and fracture healing market has been witnessing remarkable growth and innovation as healthcare professionals, pharmaceutical companies, and medical researchers seek to combat this debilitating condition. Osteoporosis is often referred to as the 'silent disease' because it progresses without symptoms until a fracture occurs. In osteoporotic individuals, bones lose their density and strength, becoming more porous and fragile. This results in a higher susceptibility to fractures, particularly in the hip, spine, and wrist. Osteoporosis predominantly affects postmenopausal women, but it can also impact men and individuals of all ages.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 14.02 Billion
Market Size 2028USD 16.76 Billion
CAGR 2023-20283.14%
Fastest Growing SegmentCalcitonin
Largest MarketNorth America

The market offers a diverse range of treatment options, including medications, medical devices, surgical procedures, and lifestyle modifications. These options aim to not only treat osteoporosis but also enhance the healing process after a fracture. Cutting-edge technologies, such as minimally invasive surgical techniques and regenerative therapies, are enhancing the effectiveness of osteoporosis treatment and fracture healing.

Key Market Drivers

Rising Aging Population is Driving the Global Anti Osteoporosis Therapy and Fracture Healing Market

The global healthcare landscape is undergoing a significant transformation, largely driven by the aging population. As people live longer, they are more likely to experience age-related health issues, one of the most common being osteoporosis. This bone disease, characterized by decreased bone density and increased fragility, poses a considerable threat to the elderly, resulting in fractures that can have debilitating consequences. The rising aging demographic has given rise to a thriving market for anti-osteoporosis therapy and fracture healing solutions.

The world's population is aging at an unprecedented rate. Advancements in healthcare, nutrition, and lifestyle choices have led to increased life expectancy. This demographic shift is observed across developed and developing countries alike, albeit at varying rates. According to the United Nations, by 2050, the global population aged 60 and above will surpass 2 billion, accounting for more than 20% of the total population. As individuals age, their bone density naturally decreases. This gradual weakening of the bones is a significant factor behind the increased prevalence of osteoporosis. Osteoporosis is often referred to as a "silent disease" because it progresses without obvious symptoms until a fracture occurs. Fractures, especially hip fractures, can have devastating consequences for the elderly, leading to reduced mobility, chronic pain, and increased mortality rates.

Growing awareness about osteoporosis and its implications on bone health has encouraged individuals to seek early diagnosis and treatment. This has driven the demand for anti-osteoporosis therapies. The development of innovative diagnostic tools and therapeutic options for osteoporosis has improved the treatment landscape. This includes medications to strengthen bones and reduce fracture risk, as well as cutting-edge surgical techniques for fracture healing. Public and private research organizations, along with pharmaceutical companies, are investing heavily in osteoporosis research. This collaboration has led to a better understanding of the disease and the development of more effective treatments.

Increasing Prevalence of Osteoporosis is Driving the Global Anti Osteoporosis Therapy and Fracture Healing Market

The increasing prevalence of osteoporosis has created a significant demand for anti-osteoporosis therapies and fracture healing solutions. This demand has spurred innovation and investment in the healthcare industry, resulting in a rapidly growing market for products and services addressing osteoporosis prevention, diagnosis, and treatment. Fractures associated with osteoporosis have substantial health and economic consequences. Hip fractures, for instance, are associated with a high mortality rate and often lead to long-term disability. Spinal fractures can result in chronic back pain, postural changes, and decreased mobility. Wrist fractures, while less severe, can still impact a person's independence and quality of life. The economic costs of treating these fractures are substantial, including hospitalization, surgery, rehabilitation, and long-term care.

Osteoporosis is more prevalent in women, especially post-menopausal women, due to hormonal changes that affect bone density. This gender disparity further fuels the growing prevalence of osteoporosis. In developing countries, where life expectancy is increasing, the burden of osteoporosis in women is likely to rise significantly.

Pharmaceutical companies have developed a range of medications that help to slow bone loss, increase bone density, and reduce fracture risk. These medications, such as bisphosphonates, selective estrogen receptor modulators (SERMs), and monoclonal antibodies, are widely prescribed for osteoporosis management. Advances in diagnostic technologies have made it easier to identify individuals at risk of osteoporosis. Dual-energy X-ray absorptiometry (DXA) scans are commonly used to measure bone density. These tools enable healthcare providers to diagnose osteoporosis early and implement interventions. In cases where fractures have already occurred, surgical solutions, such as vertebroplasty and kyphoplasty for spinal fractures, are available to provide pain relief and improve patients' quality of life. Nutrition plays a crucial role in maintaining bone health. The market for calcium and vitamin D supplements is expanding as people seek ways to support their bone density through diet and supplementation. Increasing awareness about osteoporosis and the importance of early detection and prevention has led to the development of educational campaigns and resources.

Key Market Challenges

Aging Population

One of the most significant challenges facing the market is the global aging population. As people live longer, the prevalence of osteoporosis and fractures increases. The demand for effective therapies and fracture healing solutions is surging, leading to a strain on healthcare systems and resources. This challenge necessitates the development of cost-effective and scalable treatments to meet the growing demand.

High Cost of Medications

Many anti-osteoporosis medications are expensive, making them inaccessible to a large portion of the population, especially in low- and middle-income countries. The high cost of these medications often results in delayed or inadequate treatment, which can lead to more severe health issues. Developing affordable alternatives and expanding access to these medications is a key challenge for the industry.

Lack of Awareness

Awareness about osteoporosis and fracture healing is a critical factor in early diagnosis and treatment. However, many individuals, particularly in developing countries, lack awareness about these conditions. Education and public health campaigns are essential to increase awareness, but they face hurdles in reaching remote or underprivileged communities.

Regulatory Hurdles

The development and approval of new drugs and medical devices are subject to strict regulatory processes, which can be time-consuming and expensive. Navigating these regulatory hurdles can be a major challenge for companies in the anti-osteoporosis and fracture healing market. Delays in approvals can impede the introduction of potentially life-changing therapies.

Side Effects and Efficacy

Despite advancements in drug development, some anti-osteoporosis medications come with side effects, which can deter patients from using them or lead to discontinuation. Striking a balance between efficacy and safety is a persistent challenge in this market. Additionally, not all individuals respond equally to treatments, which makes personalization a crucial aspect that researchers are trying to address.

Limited Treatment Options

While there have been significant developments in osteoporosis treatments, the market still lacks a broad range of options. This limited diversity in available therapies leaves healthcare providers with fewer choices for tailoring treatments to individual patient needs. Diversifying treatment options and exploring alternative therapies like non-pharmacological interventions remains a challenge.

Healthcare Disparities

Healthcare disparities in different regions of the world pose a significant challenge to the global anti-osteoporosis and fracture healing market. Access to healthcare, including diagnosis and treatment options, varies greatly from one region to another. Bridging these disparities and ensuring equitable access to care is a complex challenge.

Research and Development Costs

Developing new drugs, therapies, and medical devices for osteoporosis and fracture healing is expensive and time-consuming. The high costs of research and development can be a limiting factor for smaller pharmaceutical and biotech companies. Finding innovative ways to reduce R&D costs is a constant challenge for the industry.

Key Market Trends

Technological Advancements

Technological advancements have revolutionized the diagnosis of osteoporosis. Traditional methods, such as X-rays, while still valuable, have limitations. Dual-energy X-ray absorptiometry (DXA) scans are now widely used for bone density measurements, enabling early detection of osteoporosis. Furthermore, portable and cost-effective devices that use ultrasound to measure bone density are becoming increasingly accessible, allowing for early screening in primary care settings. Imaging technologies like magnetic resonance imaging (MRI) and computed tomography (CT) scans have evolved to provide better visualization of bone structure, helping doctors detect fractures and monitor healing. Three-dimensional printing and modeling have also made significant strides, allowing for the creation of personalized implants and prosthetics for patients with complex fractures. Pharmaceutical companies are investing in innovative drug development to combat osteoporosis. Targeted therapies, such as monoclonal antibodies and selective estrogen receptor modulators, are becoming available, offering a more specific and effective approach to treatment. Additionally, genetic testing and personalized medicine are contributing to the development of tailored treatment plans based on individual patients' genetics, lifestyle, and risk factors.

Telemedicine and digital health solutions are playing a crucial role in osteoporosis management. Patients can now access consultations with specialists remotely, ensuring timely and efficient care. Wearable devices and mobile apps provide tools for monitoring bone health, encouraging adherence to therapy regimens, and enabling real-time data transmission to healthcare providers for a more comprehensive approach to care. In the field of fracture healing, surgical techniques have advanced significantly. Minimally invasive procedures, such as arthroscopy, have reduced recovery times and complications associated with surgery. In orthopedics, advancements in implant materials and design have improved the success rates of joint replacements, enhancing the quality of life for patients.

The development of regenerative medicine approaches for fracture healing is a promising avenue. Stem cell therapies, tissue engineering, and growth factors are being explored to accelerate the body's natural healing processes. These techniques aim to not only repair the bone but also restore its functionality, reducing the risk of long-term complications. Artificial intelligence (AI) and data analytics are enhancing disease prediction, diagnosis, and treatment outcomes in osteoporosis. Machine learning algorithms can analyze large datasets to identify high-risk individuals and predict fractures, enabling early intervention. AI is also used to optimize drug discovery processes, potentially leading to more effective treatments.

Segmental Insights

Drug Type Insights

Based on the category of Drug Type, Calcitonin emerged as the dominant player in the global market for Anti Osteoporosis Therapy and Fracture Healing in 2022. Calcitonin is a hormone produced by the thyroid gland and plays a vital role in regulating calcium levels in the body. In the context of osteoporosis, calcitonin is particularly noteworthy for its ability to inhibit bone resorption, which is the process by which old bone tissue is broken down and replaced with new bone. This mechanism makes calcitonin a crucial component of anti-osteoporosis therapy, as it helps to preserve bone mass and prevent fractures. Numerous studies have demonstrated the effectiveness of calcitonin in slowing down bone loss and reducing the risk of fractures, making it a trusted choice for healthcare professionals. Its ability to maintain bone density and strength is a vital factor in its dominance. Calcitonin is well-tolerated by most patients and is associated with minimal side effects. This is particularly important in a market where patient comfort and safety are of utmost concern. Calcitonin is available in various administration forms, including injection, nasal spray, and oral formulations, making it suitable for a wide range of patient preferences and needs.

Distribution Channel Insights

The Hospital Pharmacies segment is projected to experience rapid growth during the forecast period. Hospital pharmacies are staffed with trained pharmacists who possess specialized knowledge about osteoporosis medications. This expertise enables them to provide guidance to healthcare professionals and patients, ensuring that the right medication is prescribed and administered correctly. Additionally, hospital pharmacies are readily accessible to patients who are already in the hospital for various reasons, making it convenient for them to receive osteoporosis treatment. Hospital pharmacies bridge the gap between inpatient and outpatient care. Patients who have undergone surgery due to fractures caused by osteoporosis often require postoperative care and rehabilitation. Hospital pharmacies can seamlessly transition patients from inpatient treatment to outpatient care, ensuring they continue their osteoporosis therapy as needed. The management of osteoporosis medication is a crucial aspect of treatment success. Hospital pharmacies closely monitor patient medication regimens, help manage side effects, and ensure adherence. This level of oversight enhances patient outcomes and reduces the risk of fractures.

Regional Insights

North America emerged as the dominant player in the global Anti Osteoporosis Therapy and Fracture Healing market in 2022, holding the largest market share in terms of value. North America boasts a highly developed healthcare infrastructure with world-class medical facilities, research institutions, and a skilled workforce. This allows for rapid innovation, research, and development of cutting-edge therapies for osteoporosis and fracture healing. The region is home to some of the world's largest pharmaceutical companies. These companies invest heavily in research and development, resulting in the creation of innovative and effective medications and therapies for osteoporosis and fracture healing. The aging population in North America, combined with lifestyle factors such as reduced physical activity and poor dietary habits, has led to a relatively high prevalence of osteoporosis. This prevalence fuels the demand for anti-osteoporosis therapies in the region.

Key Market Players

GlaxoSmithKline plc

Medtronic Plc.

Merck & Co. Inc.

Novartis AG

Pfizer inc.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd

Stryker Corporation

Teva Pharmaceutical Industries Ltd.

Orthofix US LLC

Report Scope:

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti Osteoporosis Therapy and Fracture Healing Market, By Drug Type:

  • Calcitonin
  • Bisphosphonates
  • Hormone Replacement Therapy
  • Anabolic
  • Others

Anti Osteoporosis Therapy and Fracture Healing Market, By Route of Administration:

  • Oral
  • Injectable

Anti Osteoporosis Therapy and Fracture Healing Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Anti Osteoporosis Therapy and Fracture Healing Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Anti Osteoporosis Therapy and Fracture Healing Market.

Available Customizations:

  • Global Anti Osteoporosis Therapy and Fracture Healing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, Others)
    • 4.2.2. By Route of Administration (Oral, Injectable)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Drug Type
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type
    • 5.2.2. By Route of Administration
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Type
        • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Type
        • 5.3.2.2.2. By Route of Administration
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Type
        • 5.3.3.2.2. By Route of Administration
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Type
        • 5.3.4.2.2. By Route of Administration
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Type
        • 5.3.5.2.2. By Route of Administration
        • 5.3.5.2.3. By Distribution Channel

6. Europe Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. North America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. South America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Anti Osteoporosis Therapy and Fracture Healing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Anti Osteoporosis Therapy and Fracture Healing Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. GlaxoSmithKline plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Medtronic Plc.
  • 14.3. Merck & Co. Inc.
  • 14.4. Novartis AG
  • 14.5. Pfizer inc.
  • 14.6. Eli Lilly and Co.
  • 14.7. F. Hoffmann-La Roche Ltd
  • 14.8. Stryker Corporation
  • 14.9. Teva Pharmaceutical Industries Ltd.
  • 14.10. Orthofix US LLC

15. Strategic Recommendations

16. About Us & Disclaimer